The PHLPP2 phosphatase is a druggable driver of prostate cancer progression

Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the common chromosome 16q deletion, which involves the AKT-su...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowak, Dawid G., Katsenelson, Ksenya Cohen, Watrud, Kaitlin E., Chen, Muhan, Mathew, Grinu, D’Andrea, Vincent D., Lee, Matthew F., Swamynathan, Manojit Mosur, Casanova-Salas, Irene, Jibilian, Megan C., Buckholtz, Caroline L., Ambrico, Alexandra J., Pan, Chun-Hao, Wilkinson, John E., Newton, Alexandra C., Trotman, Lloyd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548123/
https://www.ncbi.nlm.nih.gov/pubmed/31092557
http://dx.doi.org/10.1083/jcb.201902048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548123/
https://www.ncbi.nlm.nih.gov/pubmed/31092557
http://dx.doi.org/10.1083/jcb.201902048

Ejemplares similares